Versartis Inc. started a Phase I clinical trial of a treatment for growth hormone deficiency.
The Mountain View company is testing the safety and efficacy of VRS-317, a once monthly form of recombinant human growth hormone meant to be easier to use than current daily treatments.
No comments:
Post a Comment